What does this research mean for the field?

While platinum-etoposide remains the standard treatment for transformed small-cell lung cancer (T-SCLC), its benefits are transient, and emerging strategies such as anti-angiogenic therapy, chemo-immunotherapy, and novel targeted agents are needed to improve the poor prognosis of this acquired resistance mechanism in NSCLC. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize recent scientific progress in the biological mechanisms, diagnostic evaluation, disease monitoring, and therapeutic approaches for transformed small-cell lung cancer.

August 30, 2026Frontiers in MedicineOpen Access

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

View Full Paper

Ask AI

Bookmark

Authors

MWMing‐Feng WeiNational Taiwan University ZLZheng LiQingdao University KZKaiyuan ZhuUniversity of Science and Technology of China

Discussion

Member takes

Implication

Review outlines therapeutic limitations and emerging targeted options in transformed small-cell lung cancer, highlighting the need for biomarker-guided individualized regimens.

Key Points

To synthesize recent scientific progress in the biological mechanisms, diagnostic evaluation, disease monitoring, and therapeutic approaches for transformed small-cell lung cancer.
Narrative review synthesizing clinical and molecular evidence on histologic transformation as an acquired resistance mechanism in non-small-cell lung cancer.
Evaluated diagnostic tools including repeat tissue biopsy and liquid biopsy alongside therapeutic modalities comprising platinum-based chemotherapy, tyrosine kinase inhibitors, anti-angiogenic agents, and novel targeted therapies.
Transformed small-cell lung cancer carries an unfavorable prognosis with a median overall survival of approximately 9 to 13 months.
Platinum-etoposide delivers only transient disease control, while combining EGFR tyrosine kinase inhibitors with chemotherapy prolongs progression-free survival in select patients without consistently improving overall survival.
Anti-angiogenic therapy with anlotinib and chemo-immunotherapy demonstrate anti-tumor activity in subsets of patients, with emerging targets such as DLL3, MYC, SOX2, and epigenetic regulators offering potential therapeutic avenues.

Cite This Study

Wei et al. (2026) studied this question.

synapsesocial.com/papers/6a93f00a6c1a8fb52e79c12e https://doi.org/10.3389/fmed.2026.1865050

View Full Paper

Ask AI

Bookmark

Implication

Review outlines therapeutic limitations and emerging targeted options in transformed small-cell lung cancer, highlighting the need for biomarker-guided individualized regimens.

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Advanced and underlying therapeutic strategies in transformed small cell lung cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider